Search
BioMarin Pharmaceutical Inc
BMRNAdd to Watchlist
53.460USD
+0.580+1.10%
Market hours （ET）Quotes delayed by 15 min
10.33BMarket Cap
38.32P/E TTM
More Details of BioMarin Pharmaceutical Inc Company
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
BioMarin Pharmaceutical Inc Info
Ticker SymbolBMRN
Company nameBioMarin Pharmaceutical Inc
IPO dateJul 23, 1999
CEOHardy (Alexander)
Number of employees3040
Security typeOrdinary Share
Fiscal year-endJul 23
Address770 Lindaro Street
CitySAN RAFAEL
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94901
Phone14155066700
Websitehttps://www.biomarin.com/
Ticker SymbolBMRN
IPO dateJul 23, 1999
CEOHardy (Alexander)
Company Executives of BioMarin Pharmaceutical Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
127.36K
+5.90%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
52.42K
-94.66%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
35.22K
-5.48%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
21.36K
-9.03%
Ms. Barbara W. Bodem
Ms. Barbara W. Bodem
Independent Director
Independent Director
6.91K
-27.88%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
6.90K
-27.97%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
6.03K
-641.58%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
2.81K
-1848.04%
Dr. James H. Sabry, M.D., Ph.D.
Dr. James H. Sabry, M.D., Ph.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Timothy Walbert
Mr. Timothy Walbert
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
127.36K
+5.90%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
52.42K
-94.66%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
35.22K
-5.48%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
21.36K
-9.03%
Ms. Barbara W. Bodem
Ms. Barbara W. Bodem
Independent Director
Independent Director
6.91K
-27.88%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
6.90K
-27.97%
Revenue Breakdown
Currency: USDUpdated: Mon, Apr 6
Currency: USDUpdated: Mon, Apr 6
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Voxzogo
926.92M
29.26%
Vimizim
792.05M
25.00%
Naglazyme
485.40M
15.32%
Palynziq
433.31M
13.68%
Aldurazyme
208.51M
6.58%
Other
321.57M
10.15%
By RegionUSD
Name
Revenue
Proportion
United States
1.10B
34.88%
Europe
874.33M
27.60%
Rest of the world
544.47M
17.19%
Latin America
435.48M
13.75%
ALDURAZYME net product revenues marked by Sanofi
208.51M
6.58%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Voxzogo
926.92M
29.26%
Vimizim
792.05M
25.00%
Naglazyme
485.40M
15.32%
Palynziq
433.31M
13.68%
Aldurazyme
208.51M
6.58%
Other
321.57M
10.15%
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
8.41%
Dodge & Cox
7.54%
PRIMECAP Management Company
7.34%
Vanguard Capital Management, LLC
4.47%
Vanguard Portfolio Management, LLC
4.29%
Other
67.94%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
8.41%
Dodge & Cox
7.54%
PRIMECAP Management Company
7.34%
Vanguard Capital Management, LLC
4.47%
Vanguard Portfolio Management, LLC
4.29%
Other
67.94%
Shareholder Types
Shareholders
Proportion
Investment Advisor
44.15%
Investment Advisor/Hedge Fund
35.63%
Hedge Fund
10.25%
Sovereign Wealth Fund
3.90%
Research Firm
2.33%
Pension Fund
2.25%
Venture Capital
0.71%
Bank and Trust
0.67%
Individual Investor
0.28%
Institutional Shareholding
Updated: Thu, Apr 9
Updated: Thu, Apr 9
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
1355
192.89M
99.80%
-14.51M
2025Q4
1296
187.90M
108.82%
+71.66K
2025Q3
1334
187.86M
111.13%
-2.15M
2025Q2
1344
190.17M
114.04%
-8.63M
2025Q1
1331
198.83M
113.78%
-19.35M
2024Q4
1317
196.49M
110.91%
+4.70M
2024Q3
1283
191.71M
111.61%
-4.43M
2024Q2
1271
195.66M
108.22%
+2.33M
2024Q1
1257
193.46M
109.63%
-14.58M
2023Q4
1275
195.75M
103.93%
+7.49M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
16.25M
8.45%
-994.19K
-5.76%
Dec 31, 2025
Dodge & Cox
14.57M
7.58%
-114.42K
-0.78%
Dec 31, 2025
PRIMECAP Management Company
14.55M
7.57%
-679.97K
-4.46%
Dec 31, 2025
Norges Bank Investment Management (NBIM)
7.53M
3.92%
+5.49M
+268.47%
Dec 31, 2025
State Street Investment Management (US)
7.52M
3.91%
-1.24M
-14.16%
Dec 31, 2025
AQR Capital Management, LLC
6.69M
3.48%
+754.81K
+12.72%
Dec 31, 2025
Viking Global Investors LP
6.04M
3.14%
-2.29M
-27.46%
Dec 31, 2025
Dimensional Fund Advisors, L.P.
3.32M
1.73%
+1.08M
+47.95%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
First Trust NYSE Arca Biotechnology Index Fund
3.44%
Global X Genomics & Biotechnology ETF
2.98%
Invesco Biotechnology & Genome ETF
2.47%
First Trust Health Care Alphadex Fund
2.15%
Goldman Sachs Future Health Care Equity ETF
2.15%
State Street SPDR S&P Biotech ETF
1.93%
WealthTrust DBS Long Term Growth ETF
1.86%
Alger Russell Innovation ETF
1.84%
Virtus LifeSci Biotech Products ETF
1.5%
VanEck Biotech ETF
1.4%
View more
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.44%
Global X Genomics & Biotechnology ETF
Proportion2.98%
Invesco Biotechnology & Genome ETF
Proportion2.47%
First Trust Health Care Alphadex Fund
Proportion2.15%
Goldman Sachs Future Health Care Equity ETF
Proportion2.15%
State Street SPDR S&P Biotech ETF
Proportion1.93%
WealthTrust DBS Long Term Growth ETF
Proportion1.86%
Alger Russell Innovation ETF
Proportion1.84%
Virtus LifeSci Biotech Products ETF
Proportion1.5%
VanEck Biotech ETF
Proportion1.4%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
